Skip to main content

Table 5 Comparison between the two studied periods according to metabolic and inflammatory parameters in each group

From: Intermittent fasting during adjuvant chemotherapy may promote differential stress resistance in breast cancer patients

Metabolic parameters Intermittent fasting Non-fasting
Baseline After cycle 4 P Baseline After cycle 4 P
Glucose (mg/dl) (n = 24) (n = 24)   (n = 24) (n = 24)  
 Median (min.–max.) 99.50 (72.0–141.6) 98.50 (77.0–123.0) (0.516) 105.0 (82.0–161.0) 131.8 (84.0–251.0) (< 0.001***)
Insulin (µIU/ml) (n = 21) (n = 21)   (n = 20) (n = 20)  
 Median (min.–max.) 61.73 (0.0–210.0) 12.23 (0.0–165.7) (0.002**) 37.85 (0.0–210.0) 90.42 (0.0–210.0 (0.001**)
IGF1 (ng/ml) (n = 21) (n = 21)   (n = 20) (n = 20)  
 Median (min.–max.) 13.48 (2.23–50.33) 9.15 (0.0–49.85) (0.085) 8.61 (0.0–50.33) 9.90 (0.0–39.75) (0.411)
IGFBP1 (ng/ml) (n = 19) (n = 20)   (n = 14) (n = 17)  
 Median (min.–max.) 347.6 (0.0–2082.0) 274.5 (0.0–2060.3) (0.372) 297.7 (0.0–2221.9) 340.3 (0.0 – 1856.5) (0.507)
CRP (mg/L) (n = 22) (n = 22)   (n = 19) (n = 19)  
 Median (min.–max.) 4.50 (1.80–7.10) 4.10 (2.10–10.0) (0.445) 3.50 (3.0–6.20) 4.70 (3.40–10.50) (< 0.001***)
  1. IGF1 insulin-like growth factor-1, IGFBP1 IGFbinding protein 1, CRP C-reactive protein
  2. P: P value for comparing between baseline and after cycle 4 in each group
  3. *P < 0.05
  4. **P < 0.01
  5. ***P < 0.001